Over-expression of Reticulon 3 (RTN3) enhances TRAIL-mediated apoptosis via up-regulation of death receptor 5 (DR5) and down-regulation of c-FLIP

Cancer Letters

Volumn 279, Issue 2, 2009, Pages 185-192

  Lee, Jung Tae ^a   Lee, Tae Jin ^b   Kim, Cheol Hee ^c   Kim, Nam Soon ^d   Kwon, Taeg Kyu ^a  

^a Keimyung University   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Chungnam National University   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Apoptosis; c FLIP; DR5; RTN3; TRAIL

Indexed keywords

CASPASE INHIBITOR; CHIMERIC PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIBODY; FLICE INHIBITORY PROTEIN; MEMBRANE PROTEIN; RETICULON 3; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RECEPTOR UPREGULATION; SENSITIZATION;

APOPTOSIS; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 67349224064     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.01.035     Document Type: Article

References (29)

1. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 (1996) 12687-12690
2. Almasan A., and Ashkenazi A. Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14 (2003) 337-348
3. Yan R., Shi Q., Hu X., and Zhou X. Reticulon proteins: emerging players in neurodegenerative diseases. Cell. Mol. Life. Sci. 63 (2006) 877-889
4. GrandPre T., Nakamura F., Vartanian T., and Strittmatter S.M. Identification of the Nogo inhibitor of axon regeneration as a reticulon protein. Nature 403 (2000) 439-444
5. Iwahashi J., and Hamada N. Human reticulon 1-A and 1-B interact with a medium chain of the AP-2 adaptor complex. Cell. Mol. Biol. (Noisy-le-grand) 49 (2003) OL467-OL471 (Online Pub)
6. Acevedo L., Yu J., Erdjument-Bromage H., Miao R.Q., Kim J.E., Fulton D., Tempst P., Strittmatter S.M., and Sessa W.C. A new role for Nogo as a regulator of vascular remodeling. Nat. Med. 10 (2004) 382-388
7. Steiner P., Kulangara K., Sarria J.C., Glauser L., Regazzi R., and Hirling H. Reticulon 1-C/neuroendocrine-specific protein-C interacts with SNARE proteins. J. Neurochem. 89 (2004) 569-580
8. Tagami S., Eguchi Y., Kinoshita M., Takeda M., and Tsujimoto Y. A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity. Oncogene 19 (2000) 5736-5746
9. Xu H., Zhou Q., Liu X., and Qi Y.P. Co-involvement of the mitochondria and endoplasmic reticulum in cell death induced by the novel ER-targeted protein HAP. Cell. Mol. Biol. Lett. 11 (2006) 249-255
10. Kim S., Lee T.J., Leem J., Choi K.S., Park J.W., and Kwon T.K. Sanguinarine-induced apoptosis: generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL. J. Cell. Biochem. 104 (2008) 895-907
11. Lee T.J., Lee J.T., Park J.W., and Kwon T.K. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem. Biophys. Res. Commun. 351 (2006) 1024-1030
12. Deveraux Q.L., Takahashi R., Salvesen G.S., and Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388 (1997) 300-304
13. Michels J., Johnson P.W., and Packham G. Mcl-1. Int. J. Biochem. Cell. Biol. 37 (2005) 267-271
14. Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M.P., Deen K.C., McLaughlin M.M., Srinivasula S.M., Livi G.P., Marshall L.A., Alnemri E.S., Williams W.V., and Doyle M.L. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 275 (2000) 23319-23325
15. Kelley R.F., Totpal K., Lindstrom S.H., Mathieu M., Billeci K., Deforge L., Pai R., Hymowitz S.G., and Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 280 (2005) 2205-2212
16. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2001) 487-501
17. Chu L., Gu J., He Z., Xiao T., and Liu X. Adenoviral vector expressing CYLD augments antitumor activity of TRAIL by suppression of NF-kappaB survival signaling in hepatocellular carcinoma. Cancer Biol. Ther. 5 (2006) 615-622
18. Guillermet J., Saint-Laurent N., Rochaix P., Cuvillier O., Levade T., Schally A.V., Pradayrol L., Buscail L., Susini C., and Bousquet C. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc. Natl. Acad. Sci. USA 100 (2003) 155-160
19. Boehrer S., Nowak D., Puccetti E., Ruthardt M., Sattler N., Trepohl B., Schneider B., Hoelzer D., Mitrou P.S., and Chow K.U. Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis. Leuk. Res. 30 (2006) 597-605
20. Wu Y.Y., Chang Y.C., Hsu T.L., Hsieh S.L., and Lai M.Z. Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3. J. Biol. Chem. 279 (2004) 44211-44218
21. Qu X., Qi Y., Lan P., and Li Q. The novel endoplasmic reticulum (ER)-targeted protein HAP induces cell apoptosis by the depletion of the ER Ca(2+) stores. FEBS Lett. 529 (2002) 325-331
22. Kuang E., Wan Q., Li X., Xu H., Liu Q., and Qi Y. ER Ca2+ depletion triggers apoptotic signals for endoplasmic reticulum (ER) overload response induced by overexpressed reticulon 3 (RTN3/HAP). J. Cell. Physiol. 204 (2005) 549-559
23. Safa A.R., Day T.W., and Wu C.H. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr. Cancer Drug Targets 8 (2008) 37-46
24. Hyer M.L., Croxton R., Krajewska M., Krajewski S., Kress C.L., Lu M., Suh N., Sporn M.B., Cryns V.L., Zapata J.M., and Reed J.C. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 65 (2005) 4799-4808
25. Palacios C., Yerbes R., and Lopez-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res. 66 (2006) 8858-8869
26. Son Y.G., Kim E.H., Kim J.Y., Kim S.U., Kwon T.K., Yoon A.R., Yun C.O., and Choi K.S. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res. 67 (2007) 8274-8284
27. Wan Q., Kuang E., Dong W., Zhou S., Xu H., Qi Y., and Liu Y. Reticulon 3 mediates Bcl-2 accumulation in mitochondria in response to endoplasmic reticulum stress. Apoptosis 12 (2007) 319-328
28. Zhu L., Xiang R., Dong W., Liu Y., and Qi Y. Anti-apoptotic activity of Bcl-2 is enhanced by its interaction with RTN3. Cell Biol. Int. 31 (2007) 825-830
29. Xiang R., Liu Y., Zhu L., Dong W., and Qi Y. Adaptor FADD is recruited by RTN3/HAP in ER-bound signaling complexes. Apoptosis 11 (2006) 1923-1932